The company has a diverse pipeline of first-in-class assets, including Tedopi, a T-cell specific immunotherapy with positive results in non-small cell lung cancer. OSE Immunotherapeutics also has partnerships with Servier, Veloxis, and Boehringer Ingelheim for the development of other promising therapies. Additionally, the company has two proprietary drug discovery platforms, BiCKI and Myeloid, which aim to deliver next-generation immunotherapies. OSE Immunotherapeutics is based in Nantes, France and was founded in 2016.